- Home
- USBC vs NPCE Comparison
USBC vs NPCE Comparison
Compare USBC & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USBC | NPCE |
|---|---|---|
| Founded | N/A | 1997 |
| Country | | United States |
| Employees | 6 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 333.2M | 328.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | USBC | NPCE |
|---|---|---|
| Price | $0.69 | $16.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | N/A | ★ 218.4K |
| Earning Date | N/A | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $94,864,000.00 |
| Revenue This Year | N/A | $24.82 |
| Revenue Next Year | N/A | $0.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | N/A | $7.56 |
| 52 Week High | N/A | $18.98 |
Technical Indicators
Market Signals| Indicator | USBC | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 40.94 | 56.98 |
| Support Level | $0.68 | $15.98 |
| Resistance Level | $0.74 | $16.94 |
| Average True Range (ATR) | 0.06 | 0.60 |
| MACD | -0.00 | -0.18 |
| Stochastic Oscillator | 10.04 | 44.74 |
Price Performance
Historical ComparisonAbout USBC USBC Inc.
USBC Inc is a non-invasive medical diagnostics. The group is focused on the development and commercialization of proprietary sensor technology utilizing radio and microwave dielectric spectroscopy. Its Sensor technology elicits a dielectric response that is different for every molecule. The group considers the business to currently have one operating segment: the development of its radio frequency spectroscopy technology, with a first focus on non-invasively ascertaining blood glucose levels.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.